CalciMedica Pauses Auxora Trial Enrollment, Awaits FDA Feedback on Pivotal Program in Q3
CALC sits 30% above its 52-week low of $0.461 on elevated volume (51× avg).
Summary
CalciMedica has paused enrollment in its Auxora trial since January 2026 and amended it in March, now awaiting FDA feedback on a potential pivotal program in Q3. This follows positive Phase 2b results for Auxora reported in May. While the company recently secured $15 million in new financing, the pause in a lead candidate's trial introduces significant uncertainty for this micro-cap biotech. Traders should watch for the FDA feedback expected in Q3 2026.
At the time of this announcement, CALC was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.46 to $7.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.